Erythropoietin Drugs Market By Drug Type (Epoetin-Alfa, Epoetin-Beta, Darbepoetin-Alfa), By Application Type (Anemia, Kidney Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

Erythropoietin is a growth-regulating hormone that stimulates the production of red blood cells. Red blood cells are produced in the bone marrow and help carry oxygen throughout the body. Erythropoietin drugs are used to treat anemia caused by chronic kidney diseases, cancer treatment, or HIV. There are different types of erythropoietin drugs available on the market, such as Procrit, Epogen, and Aranesp. Epogen is the first blockbuster biologic for anemia approved by the FDA and is widely used. The rising prevalence of renal diseases, cancer, and HIV is driving the erythropoietin drug market.

The report titled "Erythropoietin Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall erythropoietin drug market, along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on the type of drug, application, and different geographies. The product types studied for analyzing the overall global erythropoietin drugs market are majorly segmented into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. The global erythropoietin drugs market is segmented by application type into cancer, hematology, renal diseases, and neurology.

Geographically, the global erythropoietin drug market is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Mexico
  • Brazil
  • Rest of LATAM
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year. This section also includes additional cross-sectional data in terms of drug type, applications, constituent region, and country-level markets.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global erythropoietin drugs market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive scenario of the global erythropoietin drugs market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global erythropoietin drugs market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the vascular grafts market. The key players profiled in this report are Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy's Laboratories Ltd., F. Hoffman-La Roche Ltd., Hospira, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and others.

Based on the type of application, the global erythropoietin drugs market is segmented as follows:

  • Anemia (from cancer and HIV)
  • Cancer
  • HIV
  • Kidney Disorders
  • Others

Currently, kidney disorders occupy a large share of the global erythropoietin drug application market due to the rising incidence of renal diseases. Amgen's blockbuster drug Epogen was the first to be approved by the FDA for the treatment of anemia arising from chronic kidney diseases. Therefore, being the first in the market and having a high adoption rate led to the dominance of kidney disorders in the market. Anemia occurring due to cancer and HIV is the fastest-growing segment of the erythropoietin drug market. The rising prevalence of cancer and the corresponding high usage of chemotherapeutic treatments that cause a reduction in the count of RBCs are commonly observed phenomena that fuel the demand for global erythropoietin drugs.

Based on the type of drug, the global erythropoietin drugs market is segmented as follows:

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin alfa
  • Others

Epoetin-alfa occupies the largest revenue share and dominates the global erythropoietin drug market. Amgen's Epogen (Epoetin–alfa) was the first billion-dollar product of the biotech industry that is widely used by physicians. It is the first biologic drug approved for the treatment of anemia occurring due to cancer, HIV, and chronic kidney disease. Epoetin-beta, a recombinant of Epo-alpha, also occupies a significant share due to its better efficacy than alpha. Darbepoetin alfa is anticipated to be the fastest-growing segment in the forecast period of 2017–2025. It is also an Amgen product branded as Aranesp, a higher version of Epogen with fewer side effects and higher potency. With patent expiration, the biologics segment will decline, paving the way for biosimilars in the market.

For the purpose of this study, the global erythropoietin drugs market is geographically categorized into:

  • North America (U.S., Canada)
  • Europe (U.K., Germany, and the Rest of Europe)
  • Asia Pacific (China, Japan, and the Rest of Asia)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Middle East and Africa (UAE, Saudi Arabia, South Africa, and the Rest of the Middle East and Africa)

In 2016, North America dominated the erythropoietin drug market, followed by Europe. The rising prevalence of chronic kidney diseases, cancer, and HIV is the key reason for the growth observed in the erythropoietin drug market in this region. According to the National Chronic Kidney Diseases Fact Sheet, around 15% of US adults suffer from CKD. Around 1.1 million people in the U.S. are living with HIV, which bears a huge burden in terms of mortality and morbidity. Well-established healthcare infrastructure, favorable reimbursement policies for chronic diseases, and extensive research and development for novel drugs are some of the major factors that further fuel the growth of the erythropoietin drug market in North America. Most of the key players are based in this region and are strategically expanding and strengthening their distribution networks, thus raising their revenue share. Asia Pacific is anticipated to be the fastest-growing market in the forecast period of 2017–2025. Asia Pacific has a massive population pool that is constantly growing, resulting in an increase in the incidence of chronic diseases, which would increase the demand for low-cost drugs. Hence, Asia-Pacific would be the most lucrative market for upcoming biosimilars-producing companies. Government funding would also drive the erythropoietin drug market by improving healthcare infrastructure. 

Frequently Asked Questions:

The market for Erythropoietin Drugs is expected to reach US$ 19,653.2 Mn in 2025

The Erythropoietin Drugs market is expected to see significant CAGR growth over the coming years, at 9%

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Amgen, Inc.,Biocon Limited,Celltrion, Inc.,Dr. Reddy’s Laboratories Ltd.,F. Hoffman-La Roche Ltd. are some of the major players in the global market.



Choose License Type
Trusted By
Published Date:  Jul 2017
Category:  Pharmaceuticals
Report ID:   58548
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support